2CB-2OCD3, also known as 2-trideuteromethoxy-2C-B, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families.[1][2] It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 2 position have been replaced with the deuterium isotopes.[1][2] The drug shows similar serotonin 5-HT2A receptor pharmacodynamics and metabolism as 2C-B in vitro.[1][2] The chemical synthesis of 2CB-2OCD3 has been described.[1][2] 2CB-2OCD3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI).[1][2] It was patented in 2024[2] and was first described in the scientific literature in 2026.[1]
 | |
| Clinical data | |
|---|---|
| Other names | 2C-B-2-OCD3; 2-Trideuteromethoxy-2C-B; 4-Bromo-2-trideuteromethoxy-5-methoxyphenethylamine; 2-(4-Bromo-5-methoxy-2-(methoxy-d3)phenyl)ethan-1-amine |
| Drug class | Serotonin 5-HT2A receptor agonist; Possible serotonergic psychedelic or hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C10H14BrNO2 |
| Molar mass | 260.131 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
edit- 2C (psychedelics)
- 2CB-5OCD3 (5-trideuteromethoxy-2C-B)
- 4-D (4-trideuteromescaline)
References
edit- 1 2 3 4 5 6 Cozzi NV (June 2026). "Serotonin 2A receptor binding, functional activity, and in vitro metabolism of two trideuteromethoxy 2C-B isotopologues". Naunyn-Schmiedeberg's Archives of Pharmacology. doi:10.1007/s00210-026-05566-5. PMID 42313138.
- 1 2 3 4 5 6 US 20240408038, Daley PF, Cozzi NV, "Substituted phenylalkylamines", published 2024-12-12, issued 2025-11-11, assigned to Alexander Shulgin Research Institute Inc
 | This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information. |